ALK and non-small cell lung carcinoma: Alectinib has demonstrated significant efficacy in patients who have previously progressed on crizotinib, as highlighted in the ALUR study, which showed superior PFS compared with chemotherapy for those with ALK-positive NSCLC.18] Specifically, the median duration of response for alectinib was reported at 13.5 months for crizotinib-failed patients, outperforming other next-generation ALK inhibitors like ceritinib and brigatinib, which had a median duration of responses of 8.2 and 9.3 months, respectively.